Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12348299 | 0.89 | HSD17B10 (0.36) | LMNAHSD17B10CA1CA2ALOX15 | |
| SCHEMBL18810393 | 0.87 | NR1H2 (0.56) | LMNAMAPTHSD17B10CA1CA2 | |
| SCHEMBL566487 | 0.79 | CES2 (0.46) | LMNACA1CA2ALOX15CA12 | |
| SCHEMBL14393516 | 0.77 | LMNA (0.48) | LMNAMAPTHSD17B10CA1CA2 | |
| SCHEMBL5900818 | 0.77 | PRMT5 (0.30) | HSD17B10HPGDALDH1A1CYP2C19 | |
| SCHEMBL409541 | 0.77 | HDAC1 (0.54) | LMNAMAPTCA1CA2MEN1 | |
| SCHEMBL193570 | 0.77 | CES2 (0.44) | CA1CA2MEN1KMT2ANPC1 | |
| SCHEMBL2945608 | 0.77 | LMNA (0.54) | LMNAMAPTHSD17B10CA1CA2 | |
| SCHEMBL4619841 | 0.77 | PLAU (0.54) | LMNAMAPTHSD17B10CA1CA2 | |
| SCHEMBL641475 | 0.77 | LMNA (0.50) | LMNAMAPTCA1CA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606548-B2 | Fungicidal oxadiazoles | FMC CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240166638-A1 | FUNGICIDAL OXADIAZOLES | FMC CORP (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4361150-A2 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | FMC Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240090503-A1 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | FMC CORPORATION | 2024-03-21 | — | — | US | disclosed |
| EP-4262396-A1 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | FMC CORPORATION (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11708358-B2 | Fungicidal oxadiazoles | FMC CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2022133114-A1 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | FMC CORPORATION (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| EP-3957636-A1 | FUNGICIDAL OXADIAZOLES | FMC Corporation (US) | 2022-02-23 | — | — | EP | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| CN-1568187-A | 2H-2,3-dinitrogen phenodiazine-1-ketone and using method thereof | ICOS CORP (US) | 2005-01-19 | — | — | CN | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0566199-B1 | 1,2,4-Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | SANOFI SA (FR) | 2000-03-01 | — | — | EP | disclosed |
| US-5643929-A | TREATMENT OF PICORNAVIRAL OR RHINOVIRUS AND CHEMICAL INTERMEDIATES | SANOFI WINTHROP, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5349068-A | 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | STERLING WINTHROP INC. (US) | 1994-09-20 | — | — | US | disclosed |
| US-5196535-A | Viricides | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-23 | — | — | US | disclosed |
| US-5100893-A | Viricides, effective against picorna virus, durability | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166638-A1 | FUNGICIDAL OXADIAZOLES | OXA1L, NOX1, TH | LMNA 3846/4885MAPT 224/4885HSD17B10 825/4885 |
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | LMNA 448/4885MAPT 729/4885HSD17B10 1292/4885 |
| US-12606548-B2 | Fungicidal oxadiazoles | AOC2, AOC3, MT-CO3 | LMNA 2050/4885MAPT 1233/4885HSD17B10 1163/4885 |
| US-20240090503-A1 | FUNGICIDAL OXADIAZOLES AND THEIR MIXTURES | NOX1, TH, NOX3 | LMNA 3285/4885MAPT 154/4885HSD17B10 1351/4885 |
| US-11708358-B2 | Fungicidal oxadiazoles | OXA1L, NOX1, TH | LMNA 3846/4885MAPT 224/4885HSD17B10 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.